Continuing connected transactions in relation to the revision of annual caps for the QX001S framework agreement; and resignation and proposed appointment of non-executive director
Filed with HKEX · Stock code 2509 · · 14 pages · English
Qyuns Therapeutics Co., Ltd. 江蘇荃信生物醫藥股份有限公司 (A joint stock company incorporated in the People’s Republic of China with limited liability) (Stock Code: 2509) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE REVISION OF ANNUAL CAPS FOR THE QX001S FRAMEWORK AGREEMENT; AND RESIGNATION AND PROPOSED APPOINTMENT OF NON-EXECUTIVE DIRECTOR I. CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE REVISIO
Qyuns Therapeutics Co., Ltd. on 6ix
Earlier from Qyuns Therapeutics
- 2026 Interim report
- A Decade of Persistent Steps, Aspiring for a Thousand Miles: Qyuns' Grand 10th Anniversary Celebration Held Successfully
Later from Qyuns Therapeutics
- List of directors and their roles and functions
- Voluntary announcement phase III clinical study results of Oturkibart (QX005N) for treatment of prurigo nodularis presented as a late-breaking oral presentation at EADV 2026
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Qyuns Therapeutics into a list and get an email when it puts out news.
Follow Qyuns Therapeutics